latest update:
[TrialBase DB]

trial summary · NCT07262983

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

A Pilot Study to Evaluate the Safety and Tolerability of Baricitinib in Patients With Job s Syndrome With Lupus-like Disease and/or Atopic Dermatitis

Trial record from the TrialBase DB dataset, status RECRUITING, condition Hyper IgE Syndrome From STAT3 Mutation, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07262983phase PHASE1enrollment 20start 2026-11-04

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Background: Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects the immune system. It can cause skin and lung infections and problems with blood vessels, connective tissues, and bones. People with HIES often have lupus-like disease or atopic dermatitis (skin rash). Researchers want to know if a drug approved to treat other immune system diseases (baricitinib) can help people with HIES. Objective: To test baricitinib in people with HIES with lupus-like disease or skin rash. Eligibility: People aged 12 years and older with HIES with lupus-like disease or skin rash. Design: Participants will have 5 clinic visits, 4 remote visits, and 2 phone visits in 9 months. Participants will be screened. They will have a physical exam with blood and urine tests. They will have tests of the speed and pressure of blood flow through their body: Blood pressure cuffs will be placed on each arm and leg; electrodes will be placed on the wrists and a microphone on the chest. The study has a 3-month lead-in period. Participants will not take the study drug during this time. They will continue with their usual medical care. They will have 2 phone calls with the study team. Baricitinib is a tablet taken by mouth. Participants will take 1 or 2 tablets by mouth every day for 6 months. They will start with a low dose and may increase to a higher dose. Blood and urine tests will be repeated during each study visit. Other tests may also be repeated during some visits. A skin sample may also be taken....

Source record: https://clinicaltrials.gov/study/NCT07262983

Facts

registry idNCT07262983
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionHyper IgE Syndrome From STAT3 Mutation
sponsorNational Institute of Allergy and Infectious Diseases (NIAID)
sponsor classNIH
enrollment20
start date2026-11-04
primary completion2030-05-01
completion2030-10-01
results postednot reported

Conditions

  • Hyper IgE Syndrome From STAT3 Mutation
  • Job s Syndrome
  • HIES
  • Lupus
  • Atopic Dermatitis

Interventions

  • baricitinib

Countries

  • United States

Intervention types: DRUG

Work with this record